A Multi-Center, Open Label, Two Part, Dose Escalation Study To Determine The Tolerability Of Interferon-Beta Gene Transfer (BG00001) [interferon-beta gene therapy] In The Treatment Of Recurrent Or Progressive Glioblastoma Multiforme ...
Immunotherapy with Interferon-beta (IFN beta) results in remarkably beneficial effects in patients with relapsing-remitting multiple sclerosis (MS), although the mechanisms by which it exerts these beneficial effects remain poorly understood. An investigation was made of the effects of IFN beta on pro-inflammatory and anti-inflammatory cytokine production in peripheral blood cells in MS patients, both untreated and those undergoing immunotherapy. as well as in healthy controls. Results show a significant increase in the production of pro-inflammatory cytokines such as TNF alpha, IFN gamma and IL-12 in the plasma and in the supernatant of leukocyte cultures from MS patients with the untreated disease; IFN beta administration significantly reduced the levels of TNF alpha and IFN gamma, with no changes in the level of IL-12. The Interferon-beta therapy also led to a significant increase in the production of IL-10, as well as a slight increase in that of TGF beta. The reduction in pro-inflammatory ...
Blurred vision, weak limbs, tingling sensations, unsteadiness and fatigue are the symptoms of one of the most common diseases of the central nervous system, the multiple sclerosis (MS). It is estimated that MS currently affects over 2,500,000 people worldwide. There is new hope for MS patients: The protein Interferon-beta, which is produced in bacterial or mammalian cells by genetic engineering, is being used successfully in the treatment of multiple sclerosis. However, the very high hydrophobicity and thus poor solubility of Interferon-beta, proves to be problematic for the production and clinical efficacy of recombinant human Interferon-beta.. In order to solve this problem, scientists from the German Fraunhofer Institute for Interfacial Engineering and Biotechnology (Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB) designed variants of recombinant human Interferon-beta whose solubility is improved. They replaced the hydrophobic portions of the molecule by soluble ones. ...
Human IFN Beta ELISA kit with LLOQ 1.2 pg/ml for quantitation of IFN-beta in normal human serum and plasma, autoimmune disease sera and plasma, and cell culture media
Multiple sclerosis (MS) is an inflammatory demyelinating disease affecting young adults (with a peak of onset between the ages of 20 and 40 years). In 80-90\% of cases, it is characterized by an early relapsing-remitting (RR) inflammatory phase, followed by a secondary progressive course in which disability progressively accumulates. Interferon-beta (IFNbeta) therapies represent the first-line treatment of RRMS. There are three IFNbeta formulations currently licensed for RRMS. Two are formulations of INFbeta-1a, one administered at a dosage of 30 mug intramuscularly weekly (Avonex(R)) and the other administered at a dosage of 22 or 44 microg subcutaneously (SC) three times a week (Rebif(R) 22 and 44). The third is a formulation of IFNbeta-1b, administered at a dosage of 250 microg SC every other day (Betaseron(R)). These treatments reduce the frequency of acute relapses and, to a lesser extent, disability progression. However, when starting an IFNbeta therapy, a treatment discontinuation rate ...
PURPOSE: To study the effect of oxidation on the structure of recombinant human interferon beta-1a (rhIFNbeta-1a) and its immunogenicity in wild-type and immune-tolerant transgenic mice. METHODS: Untreated rhIFNbeta-1a was degraded by metal-catalyzed oxidation, H(2)O(2)-mediated oxidation, and guanidine-mediated unfolding/refolding. Four rhIFNbeta-1a preparations with different levels of oxidation and aggregation were injected intraperitoneally in mice 15x during 3 weeks. Both binding and neutralizing antibodies were measured. RESULTS: All rhIFNbeta-1a preparations contained substantial amounts of aggregates. Metal-catalyzed oxidized rhIFNbeta-1a contained high levels of covalent aggregates as compared with untreated rhIFNbeta-1a. H(2)O(2)-treated rhIFNbeta-1a showed an increase in oligomer and unrecovered protein content by HP-SEC; RP-HPLC revealed protein oxidation. Guanidine-treated rhIFNbeta-1a mostly consisted of dimers and oligomers and some non-covalent aggregates smaller in size than ...
Like many other therapeutic proteins, recombinant human interferon beta (rhIFN-β) elicits undesirable immune responses. rhIFN-β-treated multiple sclerosis patients may form binding antibodies and neutralizing antibodies (NAbs), with the latter being responsible for inhibition of the therapeutic effect of the protein. The incidence of binding antibodies and NAbs against rhIFN-β as well as the titer and persistence of NAbs differ among the marketed products. The proportion of patients forming antibodies against rhIFN-β-1b is higher than that against rhIFN-β-1a, which is likely explained by the differences in protein structure and aggregation behavior between the 2 types of rhIFN-β. Here, we summarize the different factors influencing the immunogenicity of rhIFN-β in patients with multiple sclerosis and discuss the role played by rhIFN-β aggregates.. ...
BENEFIT is a multi-center trial conducted at 98 sites in 20 countries and included patients presenting with a first clinical episode suggestive of MS and typical MRI findings. The primary outcome measures are time to diagnosis of CDMS (Clinically Definite MS), time to confirmed EDSS (Expanded Disability Status Scale) progression and patient reported Quality of Life outcomes (FAMS-TOI). A total of 468 patients were randomized to receive either 250 micrograms of interferon beta-1b (Betaferon®) every other day or placebo as a subcutaneous injection in a double-blind fashion. The placebo-controlled treatment period lasted up to 24 months or up to the time when patients experienced a second attack and were diagnosed with clinically definite MS. All study participants were then invited to participate in a follow-up study with Betaferon® to prospectively assess the impact of such early versus delayed treatment with Betaferon® on the long-term course of the disease for a total observation time of ...
Interferon beta-1b is a cytokine in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. It is administered by sub-cutaneous injection and has been advertised as a way to slow the advance of the affliction as well as reduce the frequency of attacks. Closely related is interferon beta 1a, also indicated for MS, and with a very similar drug profile. The assertion that interferon beta in either form can slow the advance of disability in multiple sclerosis is still unproven. Interferon beta balances the expression of pro- and anti-inflammatory agents in the brain, and reduces the number of inflammatory cells that cross the blood brain barrier. Overall, therapy with interferon beta leads to a reduction of neuron inflammation. Moreover, it is also thought to increase the production of nerve growth factor and consequently improve neuronal survival. Interferon beta-1b is available only in ...
SEA222Hu, ELISA Kit for Interferon Beta (IFNb), IFNB1; IFN-B; IFB; IFF; IFNB; Interferon Beta 1 Fibroblast | Products for research use only!
METHODS: The analysis included two large, independent datasets of RRMSers who were treated with interferons that included 4-year follow-up data. The first dataset ("training set") comprised of 373 RRMSers from a randomized clinical trial of subcutaneous interferon beta-1a. The second ("validation set") included an observational cohort of 222 RRMSers treated with different interferons. The new scoring system, a modified version of that previously proposed by Rio et al., was first tested on the training set, then validated using the validation set. The association between disability progression and risk group, as defined by the score, was evaluated by Kaplan Meier survival curves and Cox regression, and quantified by hazard ratios (HRs). ...
Interferon beta-1b is made from human proteins. Interferons help the body fight viral infections. Interferon beta-1b is used to treat relapsing multiple sclerosis (MS). This medicine will not cure MS, it will only decrease the frequency of relapse symptoms. Interferon beta-1b may also be used for purposes not listed in...
Interferon Beta-1a - Get up-to-date information on Interferon Beta-1a side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Interferon Beta-1a
View drug interactions between interferon beta-1a and interferon beta-1b. These medicines may also interact with certain foods or diseases.
Conflicting reports exist regarding the requirement for virus replication in interferon (IFN) induction by paramyxoviruses. Our previous work has demonstrated that pathogen-associated molecular patterns capable of activating the IFN-induction cascade are not normally generated during virus replication, but are associated instead with the presence of defective interfering (DI) viruses. We demonstrate here that DIs of paramyxoviruses, including parainfluenza virus 5, mumps virus and Sendai virus, can activate the IFN-induction cascade and the IFN-β promoter in the absence of virus protein synthesis. As virus protein synthesis is an absolute requirement for paramyxovirus genome replication, our results indicate that these DI viruses do not require replication to activate the IFN-induction cascade.
This protein specifically binds to the DNA sequence 5-GGGACTTTCC-3 which is found in the enhancer elements of numerous viral promoters such as those of SV40, CMV, or HIV1. In addition, related sequences are found in the enhancer elements of a number of cellular promoters, including those of the class I MHC, interleukin-2 receptor, somatostatin receptor II, and interferon-beta genes. It may act in T-cell activation.
Binding of interferon beta-1b to these receptors induces the expression of a number of substances which are considered as mediators of biological effects of interferon beta-1b. The content of some of these substances were determined in serum and fractions of blood cells of patients treated with interferon beta-1b. Interferon beta-1b decreases the binding capacity and expression of receptors of gamma interferon enhances their dissolution. The drug increases the suppressive activity of peripheral blood mononuclear cells ...
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon® (interferon beta-1b), Copaxone® (glatiramer Acetate) or Rebif ® (interferon beta-1a).
Perini, P., Facchinetti, A., Bulian, P., Massaro, A. R., Pascalis, D. D., Bertolotto, A., Biasi, G. and Gallo, P., Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001. 12: 56-61 ...
To estimate the effect of interferon-beta-1b with an add-on of colecalciferol versus interferon-beta-1b with an add-on of placebo on MRI T2 BOD at 12 months in comparison with MRI T2 BOD at ...
Interferon-beta (IFN-beta) therapy for multiple sclerosis (MS) is associated with a potential for induction of neutralizing antibodies (NAbs). Because immune reactivity depends on changes in lipoprote
IFN beta Polyclonal Antibody from Invitrogen for Neutralization applications. This antibody reacts with Mouse samples. Supplied as 2x10^4 units unpurified antibody in whole serum with no preservative.
Rebif Rebidose with NDC 44087-0188 is a a human prescription drug product labeled by Emd Serono, Inc.. The generic name of Rebif Rebidose is interferon beta-1a.
Proteins of this family play an important role in inducing non-specific resistance against a broad range of viral infections. They also affect cell proliferation and modulate immune responses. Produced by peripheral blood leukocytes and lymphoblastoid cells, IFN-alpha is an acid stable molecule that signals through IFN-alpha/betaR, which is also used by IFN-beta. Both IFNs have similar anti-viral activity and regulate expression of MHC class I antigens. Recombinant human IFN-beta 1b produced in E. coli is a non-glycosylated 18.5 kDa protein containing 165 amino acid residues ...
SEA222Ga, ELISA Kit for Interferon Beta (IFNb), 干扰素β(IFNb)检测试剂盒(酶联免疫吸附试验法), IFNB1; IFN-B; IFB; IFF; IFNB; Interferon Beta 1 Fibroblast | 仅供体外研究使用,不用于临床诊断!请索取进口关税税单及报关单!
Interferon beta fremstillet ved rekombinant DNA-teknik i gensplejsede ovarieceller fra hamstere. Er glykosyleret og har aminosyresekvens identisk med human interferon beta.
MEDICATION GUIDE AVONEX Interferon beta-1a (Including appendix with instructions for using AVONEX Vials) Please read this guide carefully before you start to use AVONEX (a-vuh-necks) and each time your
... , Authors: Stefan Nagel, Roderick A F MacLeod. Published in: Atlas Genet Cytogenet Oncol Haematol.
1 reviews. Compare interferon beta 1 ELISA Kits from leading suppliers on Biocompare. View specifications, prices, citations, reviews, and more.
Just saw this interesting bit of news re: a study they did on the effectiveness of taking Interferon Beta 1b after the initial MS attack as opposed to waiting. The drug companies, of course, tell everyone that they should start ...
Learn about Betaseron (Interferon beta-1b) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
Contact information for help with BETASERON® (interferon beta-1b), the BETAPLUS® patient support program, and the BETACONNECT™ electronic autoinjector
Rebif® is an interferon medication. Interferons are a group of proteins that signal the bodys immune system to respond to threats, such as a virus.
Darmstadt, Germany (ots/PRNewswire) - - New data builds on companys longstanding commitment to MS Merck, a leading science and technology company, will present data from its...
PBL works hand in hand with researchers to help solve their most difficult problems. We have the ability and expertise in Assay Science that enables scientists to successfully conduct research. For over twenty-seven years PBL has grown not only in the number of products we offer, in the space we occupy, and in the number of our employees but, most importantly, we have developed a robust Assay Science knowledge base and an ability to successfully complete projects... read more. ...
Learn about the potential side effects of Avonex (interferon beta-1a). Includes common and rare side effects information for consumers and healthcare professionals.
Has anyone here at allnurses made a switch from Avonex to Rebif? Im concerned about the injection site reactions - is it a myth or reality? Did the flu like symptoms come back with the change?
I know that we have discussed the issue of taking Avonex while being sick in the past. At that time, I had only one prior experience in this area and that was that I had Avonex within roughly 24 hours ...
However, both local and systemic antibodies attempt to block the rep-lication and spread of viruses, either circulating or being shed from a cell that has been infected and killed. IgG is the most prevalent anti-body of the immunoglobulin system and is a potent opsonizing agent. The complement system of serum proteins is activated by IgM and later by IgG. They opsonize target cells for the phagocytes, which are then bound by IgM or IgG, and this is the classical pathway. Cells synthesize interferon when infected by virus; it is secreted into extracellular fluid and binds to adjacent cells. Interferon-alpha is de-rived from lymphocytes and interferon-beta from fibroblasts and other cell types. The IFNs acton certain cell genes that either catalyse or retard factors responsible for protein synthesis, which in turn re-duces mRNA translation, while another factor results in the degrada-tion of host and viral mRNA. The total result is to establish a sort of cordon of uninfectable cells around the ...
Bayer has posted healthy earnings for the second quarter, boosted by strong sales of Nexavar, Betaferon and the German firms contraceptives. - News - PharmaTimes
I was dxd in 06 w/ms as of 6 months ago i was told i dont have ms i have been on avonex for the 3 years, 6 months ago i was told to stop taking it bcause i have...
The goal of this study is to evaluate the safety, tolerability and effectiveness of oral cladribine when taken in combination with Interferon-beta (IFN-beta) therapy for the treatment of multiple sclerosis (MS).. This study will randomize around 200 subjects from approximately 50 sites located world-wide, who have experienced at least one relapse while taking IFN-beta therapy within 48 weeks prior to Screening, irrespective of disability progression. Secondary progressive multiple sclerosis (SPMS) subjects, who are still experiencing relapses, and subjects who have received disease modifying drugs (DMDs), other than IFN-beta therapy, during their MS treatment history, but are currently on IFN-beta therapy and have experienced active MS symptoms (at least 1 relapse) during the 48 weeks prior to Screening, may also be enrolled.. Subjects will be randomized in a 2:1 fashion to receive up to 4 cycles of oral cladribine or matching placebo in combination with IFN-beta therapy. Subjects who complete ...
Multiple sclerosis is a neurological disease caused by discrete plaques of demyelination at sites throughout the central nervous system caused by a T-Cell mediated immune response with an unknown trigger. It has a lifetime risk of 1:1000 in the UK, and is twice as prevalent in females with the typical onset being between 20 and 40 years of age, namely the childbearing ages.. There are many disease-modifying therapies used to treat Multiple Sclerosis. However, immunomodulatory and immunosuppressive drugs used at any stage of pregnancy may affect fetus formation and/or development.. Interferons are a group of naturally occurring macromolecules with antiviral, antiproliferative and immunomodulatory properties, and interferon beta is currently the most widely used therapy for multiple sclerosis. However, limited data in primates suggests that interferon beta may be abortifacient. Due to this and due to lack of experience with drug safety, it is usually suggested that either treatment is suspended ...
Interferon beta-1a (also interferon beta 1-alpha) is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some claims have been made that Interferons produce about an 18-38% reduction in the rate of MS relapses. Interferon beta has not been shown to slow the advance of disability. Interferons are not a cure for MS (there is no known cure); the claim is that interferons may slow the progress of the disease if started early and continued for the duration of the disease. The earliest clinical presentation of relapsing-remitting multiple sclerosis is the clinically isolated syndrome (CIS), that is, a single attack of a single symptom. During a CIS, there is a subacute attack suggestive of demyelination which should be included in the spectrum of MS phenotypes. Treatment with interferons after an initial attack decreases the risk of developing clinical definite MS. Medications are ...
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline
Type I interferon (IFN) is an important host defense cytokine against intracellular pathogens, mainly viruses. In assessing IFN production in response to group B streptococcus (GBS), we find that IFN-beta was produced by macrophages upon stimulation with both heat-killed and live GBS. Exposure of macrophages to heat-killed GBS activated a Toll-like receptor (TLR)-dependent pathway, whereas live GBS activated a TLR/NOD/RIG-like receptor (RLR)-independent pathway. This latter pathway required bacterial phagocytosis, proteolytic bacterial degradation, and phagolysosomal membrane destruction by GBS pore-forming toxins, leading to the release of bacterial DNA into the cytosol. GBS DNA in the cytosol induced IFN-beta production via a pathway dependent on the activation of the serine-threonine kinase TBK1 and phosphorylation of the transcription factor IRF3. Thus, activation of IFN-alpha/-beta production during infection with GBS, commonly considered an extracellular pathogen, appears to result from the
Cytosolic viral RNA recognition by the helicases RIG-I and MDA5 is considered the major pathway for IFN-alpha/beta induction in response to RNA viruses. However, other cytoplasmic RNA sensors, including the double-stranded RNA-binding protein kinase R (PKR), have been implicated in IFN-alpha/beta production, although their relative contribution and mechanism have been unclear. Using cells expressing nonfunctional PKR or reduced levels of kinase, we show that PKR is required for production of IFN-alpha/beta proteins in response to a subset of RNA viruses including encephalomyocarditis, Theilers murine encephalomyelitis, and Semliki Forest virus, but not influenza or Sendai virus. Surprisingly, although IFN-alpha/beta mRNA induction is largely normal in PKR-deficient cells, much of that mRNA lacks the poly(A) tail, indicating that its integrity is compromised. Our results suggest that PKR plays a nonredundant role in IFN-alpha/beta production in response to some but not all viruses, in part by regulating
Subcutaneous interferon beta-1a is an effective treatment for relapsing/remitting MS in terms of relapse rate, defined disability, and all MRI outcome measures in a dose-related manner, and it is well tolerated. Longer-term benefits may become clearer with further follow-up and investigation.
SEATTLE -- An investigational drug for relapsing-remitting multiple sclerosis showed better efficacy than interferon-beta1a (Avonex) in a head-to-head trial, it was reported here.
The detection of intracellular microbial DNA is critical to appropriate innate immune responses; however, knowledge of how such DNA is sensed is limited. Here we identify IFI16, a PYHIN protein, as an intracellular DNA sensor that mediates the induction of interferon-beta (IFN-beta). IFI16 directly associated with IFN-beta-inducing viral DNA motifs. STING, a critical mediator of IFN-beta responses to DNA, was recruited to IFI16 after DNA stimulation. Lowering the expression of IFI16 or its mouse ortholog p204 by RNA-mediated interference inhibited gene induction and activation of the transcription factors IRF3 and NF-kappa B induced by DNA and herpes simplex virus type 1 (HSV-1). IFI16 (p204) is the first PYHIN protein to our knowledge shown to be involved in IFN-beta induction. Thus, the PYHIN proteins IFI16 and AIM2 form a new family of innate DNA sensors we call AIM2-like receptors (ALRs ...